Stay updated on Nivolumab with Bevacizumab in Glioblastoma Clinical Trial
Sign up to get notified when there's something new on the Nivolumab with Bevacizumab in Glioblastoma Clinical Trial page.

Latest updates to the Nivolumab with Bevacizumab in Glioblastoma Clinical Trial page
- ChecktodayNo Change Detected
- Check7 days agoChange DetectedThe ClinicalTrials.gov page now displays the study record for a Phase 2 trial of nivolumab and bevacizumab in recurrent glioblastoma, including its design, eligibility criteria, and outcome measures, instead of a forbidden-access error.SummaryDifference52%

- Check14 days agoChange DetectedThe site footer revision changed from v3.7.2 to v3.8.0; the study record remains unavailable behind a 403 Forbidden error.SummaryDifference0.2%

- Check21 days agoChange DetectedAn NIH banner announces a transition in terminology from “Artificial Intelligence” to “Super Intelligence” and links to updates and FAQs.SummaryDifference1%

- Check28 days agoChange DetectedThe footer now identifies the site as revision v3.7.2 instead of v3.7.1. The page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check35 days agoChange DetectedThe footer’s displayed site revision changes from v3.7.0 to v3.7.1 while the page remains a 403 Forbidden error.SummaryDifference0.2%

- Check56 days agoChange DetectedRevision: v3.7.0 added. A large set of core study metadata, including investigators and locations, eligibility criteria, and study record details, was removed.SummaryDifference19%

Stay in the know with updates to Nivolumab with Bevacizumab in Glioblastoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab with Bevacizumab in Glioblastoma Clinical Trial page.